Oncternal Therapeutics, Inc.

... ...
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.03%36.710.9%$1161.89m
JNJJohnson & Johnson -0.01%160.280.7%$1077.05m
LLYEli Lilly & Co. 0.01%190.791.1%$703.48m
ABBVAbbVie, Inc. -0.03%110.491.9%$703.16m
MRKMerck & Co., Inc. 0.00%83.380.7%$683.91m
BMYBristol-Myers Squibb Co. 0.03%66.561.0%$677.82m
AZNAstraZeneca Plc 0.00%51.341.2%$630.16m
ARCTArcturus Therapeutics Holdings, Inc. 0.00%59.690.0%$205.25m
VTRSViatris, Inc. 0.00%17.050.0%$192.05m
RPRXRoyalty Pharma Plc 0.00%51.950.2%$173.88m
NVSNovartis AG 0.00%95.630.2%$170.63m
GSKGlaxoSmithKline Plc -0.01%38.470.2%$140.21m
SNYSanofi 0.00%49.390.2%$113.78m
RGENRepligen Corp. 0.00%215.476.9%$75.65m
NVONovo Nordisk A/S 0.00%72.030.1%$70.83m

Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. It focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.